menu
    • menu
    [{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ Neotx","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Neotx"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ NeoTX therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX therapeutics"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Active Biotech \/ NeoTX","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Oncode Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Oncode Institute","highestDevelopmentStatusID":"4","companyTruncated":"Active Biotech \/ Oncode Institute"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Laquinimod","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Active Biotech \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Active Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Active Biotech

    Menu

    Active Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Wistar Institute of Anatomy and Biology

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy

                            Details : Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.

                            Brand Name : ABR-215050

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 22, 2024

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Wistar Institute of Anatomy and Biology

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Active Biotech Strengthens the Patent Protection for Laquinimod in Eye Disorders

                            Details : Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.

                            Brand Name : TV-5600

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 26, 2022

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oncode Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Active Biotech Enters Into Global Patent License Agreement with Oncode Institute for Tasquinimod in Myelofibro...

                            Details : Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Ac...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oncode Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Preclinical Tasquinimod Data Presented at ASH 2021 Available on Active Biotech’s Website

                            Details : Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2021

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod  

                            Details : A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.

                            Brand Name : ABR-215062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 10, 2021

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : NeoTX Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech’s Partner NeoTX at ...

                            Details : Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.

                            Brand Name : ABR-217620

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 30, 2021

                            Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : NeoTX Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Follow...

                            Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2021

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : NeoTX Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Active Biotech Provides Status Update of its Clinical Naptumomab Project

                            Details : The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.

                            Brand Name : NAP

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 05, 2021

                            Lead Product(s) : Naptumomab Estafenatox,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : NeoTX Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : Famar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Active Biotech Enters into a Manufacturing Agreement with Famar Health Care Services for New Formulation of La...

                            Details : Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.

                            Brand Name : ABR-215062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 04, 2021

                            Lead Product(s) : Laquinimod

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : Famar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naptumomab estafenatox,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : NeoTX Therapeutics

                            Deal Size : $71.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Active Biotech Receive Milestone Payment From Neotx

                            Details : In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.

                            Brand Name : ABR-217620

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 11, 2020

                            Lead Product(s) : Naptumomab estafenatox,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : NeoTX Therapeutics

                            Deal Size : $71.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth